Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae

Infection Control and Hospital Epidemiology

Volumn 36, Issue 8, 2015, Pages 981-985

  Ofer Friedman, Hadas ^a   Shefler, Coral ^b   Sharma, Sarit ^c   Tirosh, Amit ^a   Tal Jasper, Ruthy ^b   Kandipalli, Deepthi ^c   Sharma, Shruti ^c   Bathina, Pradeep ^c   Kaplansky, Tamir ^a   Maskit, Moran ^a   Azouri, Tal ^a   Lazarovitch, Tsilia ^a   Zaidenstein, Ronit ^a   Kaye, Keith S ^c   Marchaim, Dror ^a,b  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM DERIVATIVE; DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ARTICLE; BACTERIUM CULTURE; BLOODSTREAM INFECTION; CLINICAL OUTCOME; CONTROLLED CLINICAL TRIAL (TOPIC); ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; FUNCTIONAL STATUS; HOSPITAL MORTALITY; HOSPITALIZATION; HUMAN; INFECTION CONTROL; INTENSIVE CARE UNIT; LENGTH OF STAY; META ANALYSIS (TOPIC); MINIMUM INHIBITORY CONCENTRATION; MORTALITY RATE; MULTICENTER STUDY (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PROTEUS MIRABILIS; URINARY TRACT INFECTION; ABDOMINAL INFECTION; AGED; ANALOGS AND DERIVATIVES; BACTEREMIA; BACTERIAL PNEUMONIA; BACTERIAL SKIN DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; FEMALE; MALE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; SOFT TISSUE INFECTION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; CARBAPENEMS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HOSPITAL MORTALITY; HUMANS; INTRAABDOMINAL INFECTIONS; LENGTH OF STAY; MALE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; PNEUMONIA, BACTERIAL; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 84988847909     PISSN: 0899823X     EISSN: 15596834     Source Type: Journal    
DOI: 10.1017/ice.2015.101     Document Type: Article

References (28)

1. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005;18:657-686.
2. Ben-Ami R, Rodriguez-Bano J, Arslan H, et al. A multinational survey of risk factors for infection with extended-spectrum betalactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009;49:682-690.
3. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and metaanalysis. J Antimicrob Chemother 2007;60:913-920.
4. Bush K. Extended-spectrum beta-lactamases in North America, 1987-2006. Clin Microbiol Infect 2008;14(Suppl 1):134-143.
5. Clinical and Laboratory Standards Institute. Performance standards for antimibrobial susceptibility testing. Nineteenth informational supplement. Approved standard M100-S19. Wayne, PA: CLSI, 2009.
6. Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004; 39:31-37.
7. Zimhony O, Chmelnitsky I, Bardenstein R, et al. Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility. Antimicrob Agents Chemother 2006;50:3179-3182.
8. Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 2010;23:160-201.
9. Bush K. Bench-to-bedside review: The role of beta-lactamases in antibiotic-resistant Gram-negative infections. Crit Care 2010;14:224.
10. Peleg AY, Hooper DC. Hospital-acquired infections due to gramnegative bacteria. N Engl J Med 2010;362:1804-1813.
11. Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A. Beta-lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012;54:167-174.
12. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extendedspectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 2012;67:2793-2803.
13. Perez F, Bonomo RA. Can we really use ss-lactam/ss-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ss-lactamase-producing bacteria Clin Infect Dis 2012;54:175-177.
14. Wooley M, Miller B, Krishna G, Hershberger E, Chandorkar G. Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam. Antimicrob Agents Chemother 2014;58: 2249-2255.
15. Sobel JD. Pathogenesis of urinary tract infection. Role of host defenses. Infect Dis Clin North Am 1997;11:531-549.
16. Retamar P, Lopez-Cerero L, Muniain MA, Pascual A, Rodriguez-Bano J. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrumbeta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 2013;57:3402-3404.
17. Marchaim D, Sunkara B, Lephart PR, et al. Extended-spectrum beta-lactamase producers reported as susceptible to piperacillintazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests. Infect Control Hosp Epidemiol 2012;33:853-855.
18. Doi Y, Park YS, Rivera JI, et al. Community-associated extendedspectrum beta-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis 2013;56:641-648.
19. Lopez-Cerero L, Navarro MD, Bellido M, et al. Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications. J Antimicrob Chemother 2014;69:809-814.
20. Marchaim D, Gottesman T, Schwartz O, et al. National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2010;54:5099-5104.
21. Chopra T, Marchaim D, Veltman J, et al. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother 2012;56:3936-3942.
22. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309-332.
23. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
24. Katz S, Ford AB,MoskowitzRW, Jackson BA, JaffeMW. Studies of illness in the aged. the index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963;185:914-919.
25. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
26. Bion JF, Edlin SA, Ramsay G, McCabe S, Ledingham IM. Validation of a prognostic score in critically ill patients undergoing transport. Br Med J (Clin Res Ed) 1985;291:432-434.
27. Collins VL, Marchaim D, Pogue JM, et al. Efficacy of ertapenem for treatment of bloodstream infections caused by extendedspectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2012;56:2173-2177.
28. Carmeli Y, Lidji SK, Shabtai E, Navon-Venezia S, Schwaber MJ, The effects of group. 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study. Diagn Microbiol Infect Dis 2011;70:367-372.